Scribe Therapeutics Wins $25M to Develop One-Shot CRISPR Heart Disease Cures
CRISPR gene therapies targeting inherited Lp(a) and triglyceride risks move closer to human trials with $25M in new funding.
Summary
Scribe Therapeutics has received over $25 million from the California Institute for Regenerative Medicine to advance two CRISPR-based gene therapies targeting inherited cardiovascular risk. The first, STX-1200, aims to permanently reduce lipoprotein(a) — an inherited risk factor for heart attacks affecting roughly one in five people worldwide that diet and exercise cannot meaningfully lower. The second, STX-1400, targets the APOC3 gene to control dangerously high triglycerides, particularly in patients with familial chylomicronemia syndrome who face pancreatitis risk. Both therapies are designed as single-treatment interventions, potentially replacing lifelong medication regimens. The funding will support moving these programs toward clinical trials, representing a significant step in treating common cardiometabolic diseases at their genetic source rather than managing symptoms after damage has already occurred.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, yet most treatments manage risk rather than address its root causes. Scribe Therapeutics is pursuing a different approach — using CRISPR gene editing to deliver one-time therapies that modify the genetic drivers of inherited heart disease. A $25 million grant from California's regenerative medicine institute is now accelerating that vision toward human trials.
The first program, STX-1200, targets lipoprotein(a), or Lp(a) — a genetically determined particle in the blood strongly linked to premature heart attacks and aortic valve disease. Unlike LDL cholesterol, Lp(a) levels cannot be meaningfully reduced through lifestyle changes. Approximately one in five people worldwide carry elevated levels, yet no approved therapy specifically targets it. STX-1200 aims to edit the gene responsible for Lp(a) production, potentially delivering lasting reduction from a single dose.
The second program, STX-1400, focuses on the APOC3 gene, a key regulator of triglyceride metabolism. Severely elevated triglycerides, as seen in familial chylomicronemia syndrome, can cause life-threatening acute pancreatitis and currently offer patients few treatment options beyond extreme dietary restriction. A durable genetic fix could transform quality of life for this population.
Both programs represent a broader shift in cardiovascular medicine — from reactive treatment after disease manifests to upstream genetic intervention before decades of arterial damage accumulate. CRISPR technology has already shown promise in rare genetic diseases, and Scribe is now applying it to conditions that affect millions.
Important caveats apply. These therapies are pre-clinical, meaning safety and efficacy in humans remain unproven. Gene editing carries inherent risks including off-target edits, and long-term durability data do not yet exist. Regulatory approval remains years away. Nevertheless, for the large share of adults carrying hidden inherited cardiovascular risk, this research trajectory is worth following closely.
Key Findings
- One in five people worldwide have elevated Lp(a), an inherited heart disease risk factor that lifestyle changes cannot fix.
- STX-1200 uses CRISPR to permanently reduce Lp(a) production from a single gene-editing treatment.
- STX-1400 targets the APOC3 gene to durably lower dangerous triglyceride levels linked to pancreatitis.
- $25M CIRM grant accelerates both programs toward human clinical trials.
- One-time gene therapies could eventually replace lifelong cardiovascular medication regimens.
Methodology
This is a news report summarizing a funding announcement from Scribe Therapeutics and the California Institute for Regenerative Medicine. Evidence basis is corporate and institutional press releases; no peer-reviewed clinical trial data is cited. Source publication, Longevity.Technology, is a credible specialist outlet but the article reflects early-stage pipeline reporting.
Study Limitations
Both therapies are pre-clinical and have not yet demonstrated safety or efficacy in humans. Long-term durability of CRISPR edits and off-target editing risks remain open questions. Regulatory approval is likely several years away at minimum; verify updates directly with Scribe Therapeutics or ClinicalTrials.gov.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: